Is Sensus Healthcare, Inc. overvalued or undervalued?

As of 15 May 2025, the valuation grade for Sensus Healthcare, Inc. has moved from very attractive to expensive, indicating a shift in market perception. The company is currently considered overvalued. Key ratios include a P/E ratio of 45, an EV to EBITDA of 20.70, and a Price to Book Value of 1.53, which are significantly higher than the industry averages.
In comparison to its peers, Kewaunee Scientific Corp. has a much lower P/E ratio of 5.90 and an EV to EBITDA of 7.23, suggesting that Sensus is trading at a premium relative to its competitors. Additionally, iCAD, Inc. is marked as risky with a negative P/E ratio, further highlighting Sensus's overvaluation in a challenging market environment. Overall, the current valuation metrics and peer comparisons suggest that Sensus Healthcare, Inc. is overvalued.